| Harmful and protective roles of neutrophils in sepsis LM Hoesel, TA Neff, SB Neff, JG Younger, EW Olle, H Gao, MJ Pianko, ... Shock 24 (1), 40-47, 2005 | 185 | 2005 |
| Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease MJ Pianko, E Terpos, GD Roodman, CR Divgi, S Zweegman, J Hillengass, ... Clinical Cancer Research 20 (23), 5888-5897, 2014 | 85 | 2014 |
| Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury LM Hoesel, MA Flierl, AD Niederbichler, D Rittirsch, SD McClintock, ... Antioxidants & redox signaling 10 (5), 963-972, 2008 | 80 | 2008 |
| Immune checkpoint blockade for hematologic malignancies: a review MJ Pianko, Y Liu, S Bagchi, AM Lesokhin Stem cell investigation 4, 2017 | 79 | 2017 |
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition MJ Pianko, SM Devlin, ER Littmann, A Chansakul, D Mastey, M Salcedo, ... Blood advances 3 (13), 2040-2044, 2019 | 61 | 2019 |
| C5a-blockade improves burn-induced cardiac dysfunction LM Hoesel, AD Niederbichler, J Schaefer, KR Ipaktchi, H Gao, D Rittirsch, ... The Journal of Immunology 178 (12), 7902-7910, 2007 | 60 | 2007 |
| Distinguishing drug from disease by use of the hydrashift 2/4 daratumumab assay KL Thoren, MJ Pianko, Y Maakaroun, CO Landgren, LV Ramanathan The journal of applied laboratory medicine 3 (5), 857-863, 2019 | 34 | 2019 |
| Immunotherapy of lymphoma and myeloma: facts and hopes MJ Pianko, AJ Moskowitz, AM Lesokhin Clinical Cancer Research 24 (5), 1002-1010, 2018 | 30 | 2018 |
| Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets UA Shah, KH Maclachlan, A Derkach, M Salcedo, K Barnett, J Caple, ... Clinical Cancer Research 28 (23), 5149-5155, 2022 | 22 | 2022 |
| Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma MJ Pianko, SA Funt, DB Page, D Cattry, EC Scott, SM Ansell, IM Borrello, ... Leukemia & lymphoma 59 (1), 221-224, 2018 | 18 | 2018 |
| Clinical development of PD-1 blockade in hematologic malignancies MJ Pianko, AD Goldberg, AM Lesokhin The Cancer Journal 24 (1), 31-35, 2018 | 16 | 2018 |
| Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma E Hoylman, A Brown, AJ Perissinotti, BL Marini, M Pianko, JC Ye, ... Leukemia & lymphoma 61 (3), 691-698, 2020 | 15 | 2020 |
| Characterization of antigenic variants of hepatitis C virus in immune evasion JH Wang, MJ Pianko, X Ke, A Herskovic, R Hershow, SJ Cotler, W Chen, ... Virology Journal 8, 1-13, 2011 | 11 | 2011 |
| Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study S Jagannath, J Richter, MV Dhodapkar, JE Hoffman, HC Lee, ... Blood 142, 4746, 2023 | 10 | 2023 |
| Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study H Mian, TM Wildes, R Vij, MJ Pianko, A Major, MA Fiala Blood cancer journal 13 (1), 76, 2023 | 10 | 2023 |
| Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia JW Smithy, MJ Pianko, C Maher, MA Postow, AN Shoushtari, P Momtaz, ... Journal of Immunotherapy 44 (1), 9-15, 2021 | 9 | 2021 |
| Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation MJ Pianko, JL Golob Cancer and Metastasis Reviews 41 (2), 367-382, 2022 | 8 | 2022 |
| Abstract CT013: Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA× CD3 bispecific antibody with low CD3 affinity, in patients with relapsed … A Suvannasankha, P Kapoor, MJ Pianko, J Richter, A D'Souza, ... Cancer Research 83 (8_Supplement), CT013-CT013, 2023 | 7 | 2023 |
| TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma. K Patel, RZ Orlowski, K Doucette, M Maris, MJ Pianko, R Ramchandren, ... Journal of Clinical Oncology 40 (16_suppl), TPS8071-TPS8071, 2022 | 7 | 2022 |
| Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach MJ Pianko, T Tiutan, A Derkach, J Flynn, SP Salvatore, I Jaffer‐Sathick, ... American journal of hematology 98 (3), 421-431, 2023 | 4 | 2023 |
